Sleep duration and psychotic experiences in patients at risk of psychosis: A secondary analysis of the EDIE-2 trial.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 05 2018
revised: 06 08 2018
accepted: 07 08 2018
pubmed: 20 8 2018
medline: 5 3 2020
entrez: 20 8 2018
Statut: ppublish

Résumé

Sleep disturbance is common among individuals at risk of psychosis, yet few studies have investigated the relationship between sleep disturbance and clinical trajectory. The Early Detection and Intervention Evaluation (EDIE-2) trial provides longitudinal data on sleep duration and individual psychotic experiences from a cohort of individuals at risk of psychosis, which this study utilises in an opportunistic secondary analysis. Shorter and more variable sleep was hypothesised to be associated with more severe psychotic experiences and lower psychological wellbeing. Mixed effect models were used to test sleep duration and range as predictors of individual psychotic experiences and psychological wellbeing over the 12-24 months (with assessments every 3 months) in 160 participants. Shorter sleep duration was associated with more severe delusional ideas and hallucinations cross-sectionally and longitudinally. The longitudinal relationships did not remain significant after conservative controls were added for the previous severity of psychotic experiences. No significant relationships were found between the sleep variables and other psychotic experiences (e.g. cognitive disorganisation), or psychological wellbeing. The results support a relationship between shorter sleep duration and delusional ideas and hallucinations. Future studies should focus on improving sleep disturbance measurement, and test whether treating sleep improves clinical trajectory in the at-risk group.

Identifiants

pubmed: 30121185
pii: S0920-9964(18)30498-5
doi: 10.1016/j.schres.2018.08.006
pmc: PMC6406020
pii:
doi:

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-333

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0500264
Pays : United Kingdom
Organisme : Department of Health
ID : RP-2014-05-003
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098461/Z/12/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Schizophr Res Treatment. 2013;2013:425826
pubmed: 23738067
BMC Med Res Methodol. 2002 Jun 17;2:8
pubmed: 12069695
Lancet Psychiatry. 2015 Nov;2(11):975-83
pubmed: 26363701
Schizophr Res. 2008 Oct;105(1-3):10-7
pubmed: 18765167
Early Interv Psychiatry. 2011 Feb;5(1):24-32
pubmed: 21272272
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Schizophr Bull. 2018 Apr 6;44(3):662-671
pubmed: 28981834
World Psychiatry. 2004 Oct;3(3):163-8
pubmed: 16633488
Behav Cogn Psychother. 2018 May;46(3):276-291
pubmed: 29081329
Schizophr Res. 2015 Dec;169(1-3):262-267
pubmed: 26391284
Psychiatry Res. 2017 Mar;249:240-243
pubmed: 28126579
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2631-7
pubmed: 24096189
BMJ. 2012 Apr 05;344:e2233
pubmed: 22491790
Behav Sleep Med. 2010;8(3):123-40
pubmed: 20582756
Br J Psychiatry. 2012 Apr;200(4):308-16
pubmed: 22194182
Schizophr Res. 2017 Nov;189:37-42
pubmed: 28169087
Clin Psychol Rev. 2015 Dec;42:96-115
pubmed: 26407540
Arch Gen Psychiatry. 2010 Mar;67(3):241-51
pubmed: 20194824
Sleep Med Rev. 2010 Feb;14(1):69-82
pubmed: 19962922
Schizophr Res. 2015 May;164(1-3):15-20
pubmed: 25818627
Sleep Med Rev. 2017 Feb;31:25-38
pubmed: 26920092
Behav Res Ther. 1997 Aug;35(8):785-91
pubmed: 9256522
Lancet Psychiatry. 2017 Oct;4(10):749-758
pubmed: 28888927
Schizophr Res. 2016 Jan;170(1):130-6
pubmed: 26673973
Int J Soc Psychiatry. 1999 Spring;45(1):7-12
pubmed: 10443245
Psychiatry Res. 2011 Aug 30;189(1):62-6
pubmed: 21257208
Psychiatry Res. 2011 May 15;187(1-2):304-6
pubmed: 21272939
Schizophr Res. 2003 May 1;61(1):19-30
pubmed: 12648732
Lancet. 2005 Apr 30-May 6;365(9470):1591-5
pubmed: 15866314
JAMA Psychiatry. 2014 Sep;71(9):985-6
pubmed: 25075582
JAMA Psychiatry. 2014 Sep;71(9):1049-57
pubmed: 25075799
Sleep Med Clin. 2015 Mar;10(1):17-23
pubmed: 26055669
Schizophr Res. 2009 Mar;108(1-3):280-4
pubmed: 19097752

Auteurs

S Reeve (S)

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. Electronic address: sarah.reeve@psych.ox.ac.uk.

A Nickless (A)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, UK.

B Sheaves (B)

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK.

J Hodgekins (J)

Norwich Medical School, University of East Anglia, Norwich, UK.

S L K Stewart (SLK)

Department of Psychology, University of Chester, Parkgate Road, Chester, UK.

A Gumley (A)

Institute of Health and Wellbeing, University of Glasgow, Gartnavel Royal Hospital, Glasgow, UK.

D Fowler (D)

School of Psychology, Pevensey Building, University of Sussex, Falmer, Brighton, UK.

A Morrison (A)

Division of Psychology and Mental Health, University of Manchester, Manchester, UK.

D Freeman (D)

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH